BMS Archive

Plant · Scientific monograph

Eleutherococcus senticosus

Eleuthero / Siberian Ginseng

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Adaptogen Research, Immune Support Research, Exercise Performance Research, Stress Response Research

Research overview

Historical use

Eleutherococcus senticosus (also known as Acanthopanax senticosus) is native to northeastern China, Japan, Korea, and Siberia, where it has been used in traditional medicine for over 2,000 years. In traditional Chinese medicine (ci wu jia), the root bark was prescribed for strengthening qi, supporting kidney and spleen function, and promoting longevity. Soviet researchers in the 1950s–1980s extensively investigated it as an adaptogen — a substance conferring non-specific resistance to physical and psychological stress — and it was administered to Soviet athletes, cosmonauts, and military personnel during this period. The term 'Siberian ginseng' was coined during this era, though it is not a true ginseng (genus Panax) and lacks ginsenosides entirely. It is pharmacologically and taxonomically distinct from Panax ginseng (index 26 in this archive). Several regulatory authorities including Health Canada and the US National Institutes of Health now recommend 'Eleuthero' as the preferred common name to prevent consumer confusion with Panax products.

Modern research context

Eleutherococcus senticosus is classified as an adaptogen with Level C evidence for stress reduction and immune modulation (Level B pending independent verification of RCT study designs in cited literature). A systematic review reported evidence for adaptogenic effects including reduced fatigue and improved physical and mental performance under stress conditions, though study quality varies [3]. Randomized trials demonstrate improvements in natural killer (NK) cell activity and T-lymphocyte counts, supporting immune-modulatory applications [1]. Evidence for exercise performance enhancement is mixed — some RCTs show modest improvements in oxygen uptake and endurance, others show no benefit; overall Level C for this indication [4]. For cognitive effects under stress (mental fatigue, attention), several controlled studies report benefit, with the Hartz 2021 RCT showing significant fatigue reduction [1]. The Soviet-era pharmacological investigations established the basic safety profile and dosing, though by modern standards many of these studies lack methodological rigour.

Adverse effects

Generally well-tolerated at standard doses. Most commonly reported adverse effects: mild insomnia (particularly with evening dosing), restlessness, and irritability — consistent with mild stimulant-like properties. Elevated blood pressure reported in a small proportion of trial participants; caution in hypertension. Mastalgia (breast tenderness) and uterine bleeding have been reported rarely in women. A digoxin-interference phenomenon was identified in early clinical practice: eleutherosides cross-react with digoxin immunoassays, producing false elevations — not a pharmacodynamic interaction but a laboratory artefact.

Contraindications

Hypertension — may mildly elevate blood pressure; use with medical monitoring. Concurrent use in patients receiving digoxin monitoring — eleutherosides cause false-positive digoxin immunoassay results; use alternative monitoring. Autoimmune disease (SLE, MS, RA) — immune stimulation may exacerbate. Pre-surgery: discontinue at least 7 days before; immunostimulant effects and possible platelet interactions. Hormone-sensitive conditions — some preliminary estrogenic activity reported.

Clinical and phytochemical data

Used part

Root and rhizome bark (dried; aqueous or ethanolic extracts). Standardized for eleutheroside B (syringin) and eleutheroside E content.

Primary active compounds

  • Eleutheroside B (syringin — phenylpropanoid glucoside) — primary quality marker

  • Eleutheroside E (syringaresinol diglucoside — lignan) — immunomodulatory

  • Eleutherosides A, B1, C, D, F, G (phenylpropanoids, coumarins, triterpenoids)

  • Polysaccharides (eleutheranes A–G) — immunostimulant

  • Isofraxidin (coumarin) — anti-inflammatory

  • Sesamin and syringaresinol (lignans)

Mechanism of action

Eleutherococcus senticosus exerts adaptogenic effects primarily through modulation of the HPA (hypothalamic-pituitary-adrenal) axis and the sympathoadrenal system, normalising cortisol and adrenaline responses to stress without producing sedation or stimulation per se [2, 3]. Polysaccharide fractions (eleutheranes) activate macrophages and natural killer (NK) cells, upregulating cytokine production including IL-1β, TNF-α, and interferon-γ, supporting innate immune defence [1, 2]. Antifatigue effects involve protection of mitochondrial function under oxidative stress and modulation of Hsp70 (heat shock protein 70) expression — a cellular stress response protein [3]. Exercise performance effects may be mediated through enhanced oxygen utilisation and reduced lactic acid accumulation, though the mechanism is not fully elucidated [4]. Anti-inflammatory activity occurs via NF-κB pathway suppression by lignan fractions.

Pharmacokinetics

Absorption

Human pharmacokinetic data are very limited. Eleutheroside B (syringin) and eleutheroside E are detected in plasma after oral administration in animal studies; human bioavailability data are not formally established in published literature. Absorption is influenced by preparation type and standardisation. Polysaccharides are poorly absorbed intact and may exert primary effects in the GI tract.

Distribution

Animal studies suggest distribution to liver, spleen, and adrenal tissue — consistent with the proposed adaptogenic mechanism. Human distribution data not available.

Metabolism

Eleutherosides undergo hepatic phase I and phase II metabolism. Syringin (eleutheroside B) is metabolized to syringyl alcohol and related phenolic metabolites. No significant CYP450 induction or inhibition has been formally characterised for eleuthero extracts. Drug interaction data are based primarily on case reports and theoretical pharmacology.

Excretion

Metabolites are excreted primarily renally. No formal human pharmacokinetic studies reporting half-life or excretion data for eleutheroside constituents. Based on structural analogues, t1/2 likely 2–6 hours for phenylpropanoid glucosides.

Safety and interactions

Drug interactions

Digoxin immunoassays: eleutheroside E cross-reacts with digoxin immunoassays, producing falsely elevated digoxin readings — this is a laboratory interference, not a pharmacodynamic interaction; alert treating clinicians if patient uses eleuthero [2]. Sedatives and anxiolytics: potential additive effects at high doses; clinical significance uncertain. Antidiabetic drugs: eleuthero may lower blood glucose in animal models; monitor blood glucose in diabetic patients. Anticoagulants: in vitro platelet inhibitory effects reported for some Eleutherococcus preparations; monitor with warfarin or antiplatelets. Immunosuppressants: immunostimulant activity may antagonise immunosuppressive therapy — contraindicated.

Toxicity

Extensive Soviet-era and subsequent research indicates low acute toxicity. LD50 in rodents is high (>3 g/kg oral). No serious adverse events in published clinical trials at standard therapeutic doses. No organ-specific toxicity identified in chronic animal studies at relevant doses. Mild insomnia and anxiety at higher doses are the primary tolerability issues documented.

Special precautions

Pregnancy

Insufficient safety data for use during pregnancy. Some traditional texts note use in post-partum recovery, but controlled data are absent. Not recommended during pregnancy. Evidence basis: absence of controlled human data.

Lactation

Insufficient safety data. Not recommended during breastfeeding.

Hepatic impairment

No formal pharmacokinetic studies in hepatic impairment. No hepatotoxicity signal in clinical trial data. Use with standard clinical caution in significant hepatic impairment; dose reduction may be prudent.

Renal impairment

No formal studies. Eleutheroside metabolites are renally excreted. Use with caution in severe renal impairment; clinical monitoring recommended.

Sources and references

  1. [1] - Hartz AJ et al., "Randomized controlled trial of Siberian ginseng", Nutrients, 2021, PMID: 34445021
  2. [2] - Huang L et al., "Eleutherococcus senticosus: pharmacological mechanisms", J Ethnopharmacol, 2019, PMID: 30243827
  3. [3] - Todorova V et al., "Plant adaptogens — evidence review", Pharm Biol, 2021, PMID: 34541998
  4. [4] - Naseri MHG et al., "Adaptogenic herbs and fatigue", Front Pharmacol, 2023, PMID: 37829299
  5. [5] - Panossian A, "Understanding adaptogenic activity", Phytomedicine, 2017, PMID: 26598919

Additional source links

Continue browsing